Company intelligence / Profile preview

Moebius Medical

Ownership: Private
Development stage: Phase 3

Overview

MM-II demonstrated safety and efficacy in a Phase IIb clinical trial. The company received Fast Track designation from the FDA for MM-II in September 2024. Phase 3 clinical development is planned to begin shortly.

Therapeutic areas: Rheumatology
Modalities: Liposomal technology (Large Liposomes of DPPC and DMPC)
Industry: Biotech

Drug pipeline

1 asset

MM-II

Phase 3

Indications: Knee osteoarthritis pain

Partnerships

Sun Pharmaceuticals Industries Ltd. (joint collaboration and license agreement formed in 2016)

Beyond the preview

Go deeper on Moebius Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moebius Medical.

Explore the full profile